Fetal RHD screening test
(only available to customers in the UK and Ireland – a service-specific contract is required)
We offer a United Kingdom Accreditation Service (UKAS) accredited fetal RHD screening service to prevent unnecessary administration of anti-D prophylaxis. The test predicts fetal RhD status with high accuracy from a sample of maternal blood and will improve care for RhD-negative women in the UK and the Republic of Ireland by reducing the need to administer a blood product to healthy pregnant women.
IBGRL have optimised and automated the testing technology applied to pregnancies at risk of haemolytic disease of the fetus and new-born (HDFN) to enable high throughput fetal RHD screening of all D negative pregnant women, who have not formed immune anti-D or anti-G to guide antenatal anti-D prophylaxis.
High-throughput non-invasive prenatal testing for fetal RHD genotype is recommended by the National Institute for Health and Care Excellence (NICE) as a cost-effective option to guide antenatal prophylaxis with anti-D immunoglobulin.
For further information about the fetal RHD screening test, please read our brochure.
This is not a diagnostic test for fetal RhD status for women who have made anti-D (or-G). Please refer to the management of pregnant women with alloantibodies.
Download our user guide for referring samples to IBGRL Molecular Diagnostics
Have a question?
Please contact the laboratory or our business development manager for more information:
If you wish to set up a contract to send samples or would like to obtain information regarding the tests performed, please contact Erika Rutherford.
For all other enquiries, please contact Molecular Diagnostics.